It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH.
His abstract entitled ‘Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial’ was presented at EASL ILC 2021, 23-26 June.
- What did the Phase 2 NN9931-4296 clinical trial teach us about the clinical utility of semaglutide in the treatment of patients with NASH? (0:10)
- Which subgroups were evaluated in the recent post-hoc analysis of the trial data? (0:54)
- What were the findings across the various subgroups, and what are the clinical implications of these findings? (1:30)
- Where do you think semaglutide will likely sit in the treatment paradigm for NASH? (2:12)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Quentin Anstee: Highlights from the Digital NAFLD Summit 2021
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Are you pleased with how the European Association for the Study of the Liver (EASL) NAFLD Summit 2021 went this year? (00:23-01:00) 2. What were […]
Quentin Anstee, Digital NAFLD Summit 2021: Exciting Advances and New Research into the Management of Non-alcoholic Fatty Liver Disease
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (00:20-01:00) 2. What are the current most […]
Jean-François Dufour, UEG 2021: Treatment Pipeline for NASH
It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!